Skip to main content

Table 2 Disease activity at 24 weeks

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

  Tofacitinib (n = 161) Baricitinib (n = 81) Crude risk ratio (95% CI) Adjusted risk ratio (95% CI)
DAS28-ESR
 Remission, n (%) 29 (18.0) 20 (24.7) 0.73 (0.44 to 1.21) 0.71 (0.44 to 1.18)
 LDA achievement, n (%) 51 (31.7) 37 (45.7) 0.69 (0.50 to 0.96) 0.68 (0.49 to 0.95)
SDAI
 Remission, n (%) 34 (21.1) 22 (27.2) 0.78 (0.49 to 1.24) 0.73 (0.46 to 1.16)
 LDA achievement, n (%) 103 (64.0) 50 (61.7) 1.04 (0.84 to 1.27) 1.03 (0.85 to 1.24)
CDAI
 Remission, n (%) 29 (18.0) 18 (22.2) 0.81 (0.48 to 1.37) 0.80 (0.47 to 1.37)
 LDA achievement, n (%) 106 (65.8) 49 (60.5) 1.09 (0.88 to 1.34) 1.11 (0.91 to 1.35)
  1. Adjusted risk ratios were estimated using a modified Poisson regression model, which included the treatment group (tofacitinib vs baricitinib) and confounders as sex, age, disease duration, MTX use, oral steroid use, the number of previous biological/target synthetic DMARD use, DAS28-ESR, SDAI, mHAQ, presence of RF, and ACPA
  2. DAS disease activity score, ESR erythrocyte sedimentation rate, LDA low disease activity, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, CI confidence interval